Saint-Nazaire: Bioanalysis, Biomarkers, and Immunogenicity

When choosing a partner, you need to consider their depth of scientific expertise, infrastructure, and program management skills. Our site in Saint-Nazaire, France has everything you need to run bioanalytical studies to evaluate preclinical and clinical drug candidates. No matter what modality you are using or therapeutic area your research is working on, we can accommodate your specifications and timelines.

Talk with Our Team

Preclinical and Clinical Assays

Through our unique position as a leading provider of nonclinical and clinical analytics, our scientists are experts at assay life cycle management. This ensures that assays and testing paradigms applicable in nonclinical research are appropriately transitioned to the clinical phase, eliminating the need for costly and often difficult method transfer between laboratories.

Facility overview of the Saint-Nazaire site with details of their bioanalysis, biomarker, and immunogenicity capacities.

See What Saint Nazaire Can Do for You

Located just outside of Nantes, France, our Saint-Nazaire site can perform small and large molecules and biomarkers bioanalysis to support clinical and nonclinical studies (discovery up to Phase III/IV clinical trials).
See Our Capabilities

From small to large molecules, and at any phase in development, Saint-Nazaire has the tools required to quantify and characterize drugs and metabolites in various animal and human biological matrices (e.g., plasma, whole blood, urine, excreta, bile, tears, CSF, tissues, etc.).

Large Molecules

For large molecules, bioanalysis assays are run by immunoassay or liquid chromatography-mass spectrometry (LC-MS/MS).

By Immunoassay

More than 30 ligand-binding assays using several techniques (ELISA, ECLIA, RIA, etc.) are developed each year to identify peptides, proteins, monoclonal and multifunctional antibodies, biosimilars/biobetters, or antibody-drug conjugates (ADC) in several matrices. Our 12 scientists will make sure they find a fit-for-purpose technique suited for your bioanalysis project(s).

The team at Saint-Nazaire has conducted more than 60 studies annually and analyzed more than 20,000 samples per year, so we have the capacity to take on your project and get the crucial data you need to make more confident go/no-go decisions.

By LC-MS/MS

The use of LC-MS/MS allows a fast development of robust and specific assays for the quantification of multiple large molecules such as peptides, proteins, monoclonal antibodies, ADC (for the antibody and the conjugate part), or oligonucleotides. The characterization of modifications, metabolites, peptide mapping is also possible for all biologics.

Our experienced team can prepare fit-for-purpose sample preparations including enzymatic digestion (e.g., trypsin) with or without immuno/affinity capture, as well as measurement in intact mode using LC-MS and HR-MS (High-resolution mass spectrometry).

 

Scientifics working together in research & development

Development and Validation of a Method by LC-MS/MS for Non-Clinical and Clinical Studies

Developing generic methods for the quantification of therapeutic antibodies by mass spectrometry in multiple matrices, with one therapeutic antibody, Pembrolizumab, an anti-PD1 compound.
Download the poster

Small Molecules

For your small molecule development, it is important to run the most sensitive and robust assays available. The following equipment allows us to reach those key points for analysis of active compounds and metabolites in various biological matrices (plasma, urine, tissues…):

  •    Automated and fit-for-purpose sample preparation (Protein crash, LLE, SPE…)
  •    Last generation LC-MS/MS (ABSciex API6500)
  •    High resolution mass spectrometry (HR-MS, Q-ToF)
  •    GC/MS

With more than 50 validations conducted and a capacity of more than 100,000 samples analyzed annually, Saint-Nazaire is ready to take on your bioanalytics testing.

Read More on Bioanalytics

With multiple platforms available to provide support to toxicology findings or PD readouts from preclinical to clinical samples (e.g., ELISA, ECLA®, chromatography (liquid/mass), RIA, ImmunoCAP [Phadia], LC-MS, HR-MS), Saint-Nazaire will be able to identify your soluble biomarkers (in single and MultiPlex) for cytokines/chemokines, hormones, immunoglobulins, complement factors, injury markers (bone, cardiac, kidney, etc.), and more.

Find the Right Biomarker for Your Project

Our biomarker database can help you ease the burden of finding the right one(s) for your project. Browse this interactive tool by therapeutic area, toxicological indication, and species, or enter in your search criteria to find what you need. Explore Our Database

Read More on Biomarkers

Saint-Nazaire can determine the presence of antibodies generated against the drug at all stages of the development process. The different steps that can be run after the development and validation of controls from screening assay to neutralizing assay are shown below.

Schema of antibody testing, where the whole process can be run together or as stand-alone steps.

Our team analyzes over 9,000 samples annually and conducts more than 40 studies, from simple screening to titration and neutralizing steps.

Read More on Immunogenicity

Meet the Team

 

Elodie Pedron Headshot

Elodie Pedron, Ing. | Group Leader Immunochemistry
Elodie is the Head of the Immunochemistry department at St Nazaire, where she manages teams’ experts in the development and validation of methods for the detection/quantification of test items (large molecules), biomarkers, anti-drug antibodies (ADA), and neutralizing antibodies (Nab) using different techniques including ELISA, electrochemiluminescence, and cell-based assays. She is graduated from the INSA engineer school and has previously acquired experience in bioanalysis from big pharma (Sanofi Pasteur, Lyon) and biotech companies (APCure, Lyon). Elodie has previously served at Atlanbio as a study manager and then Team Leader for 7 years before the company was acquired by Charles River.


Jordane Biarc Headshot

Jordane Biarc, PhD | Team Leader Chromatography
Jordane has more than 15 years of experience in biomarker and drug quantitation in academic research and CRO industries where she has developed tools and methods for the analysis of large molecules by mass spectrometry. She obtained her PhD in Cellular and Molecular Pharmacology at Louis Pasteur University in Strasbourg, France before consolidating her expertise at the University of California-San Francisco, US and the Institute of Analytical Sciences Lyon, France. In her current role, Jordane is leading the team in charge of the implementation and analysis of large molecules by LC-MS as well as HR-MS (high-resolution mass spectrometry) in CR-STN.


Laurent Turbe Headshot

Laurent Turbe, MsC | Associate Director Chromatography
Laurent is the head of the chromatography department at the St Nazaire, France site of Charles River, where he manages teams of experts in bioanalysis of small and large molecules by LC-MS/MS. He graduated from the University Paris XI-Orsay (France) with a master’s degree in instrumentation and analytical chemistry. Laurent previously served at Atlanbio as a team leader and study manager in bioanalysis for more than 12 years before the company was acquired by Charles River.


Talk to Our Team

 

Frequently Asked Questions (FAQs) About St Nazaire Facility on Bioanalysis, Biomarker & Immunogenicity

  • Is Charles River Laboratories Saint-Nazaire certified?

    For non-clinical safety studies, Charles River Laboratories Saint-Nazaire is GLP certified for the bioanalysis of human and veterinary drugs (OECD category 8). There are no certifications applicable to the bioanalytical work performed in support of clinical trials. Any phase conducted in Charles River Saint-Nazaire is consistent with the principles of GCP. The existing GLP quality system is applied and additional due diligence is exercised to ensure the clinical trial subjects' rights are not compromised. This includes conducting clinical bioanalysis in accordance with SOPs based on ICH E6, EU Directive 2001/20/EC and EU Directive 2005/28/EC, the EMA: Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, and the Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

  • Which types of companies has Saint-Nazaire worked with?

    The site has already worked with different industries of all sizes, including agrochemical, pharmaceutical, biotechnology, clinical CROs, and cosmetics.

  • What quality level do I need for bioanalysis of my molecule?

    We advise and guide our clients on the best approach to be used based on the objectives of the preclinical/ clinical study together with the technical/scientific aspects. We suggest a panel of fit-for-purpose solutions from the non GLP research-grade assay to the GLP fully validated method.

  • Can I use LC-MS/MS or an immunoassay for my large molecule?

    Yes, it is possible and will be determined on a case-by-case basis with your needs and our experts.

  • Is there a lot of adaptation to do the bioanalysis from preclinical to clinical samples?

    Our teams are trained to handle studies from both preclinical and clinical stages. Scientific expertise, instruments, and GLP environment are setup for preclinical studies provide an excellent framework for clinical sample analysis, with some additional specificities: our Site Procedures include requirements about patient safety and confidentiality; we are able to store a large volume of samples at -20°C/-70°C, with appropriate tools to manage them (Watson LIMS, barcode labels…); study follow-up includes in particular sample design reconciliation, data management (data transfer specifications, transfers), management of blinded studies in addition to bioanalytical plan and report deliveries.

 

Related Resources